1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Healthpeak reported a third-quarter 2025 net loss applicable to common shares of $117.3 million, or $0.17 per share, compared with net income of $85.7 million, or $0.12 per share, a year earlier. The loss reflects $175.8 million of impairment charges on unconsolidated joint ventures. The company cut its full-year 2025 diluted earnings per share guidance to $0.00 to $0.06 from $0.25 to $0.31, while reaffirming its Nareit FFO guidance of $1.78 to $1.84 per share.
Third-quarter Nareit FFO rose to $0.45 per share from $0.44 a year earlier; FFO as Adjusted was $0.46 versus $0.45.
Third-quarter net loss of $117.3 million ($0.17 per share) included $175.8 million of impairments on unconsolidated joint ventures.
2025 diluted EPS guidance lowered to $0.00 to $0.06 from $0.25 to $0.31; Nareit FFO guidance of $1.78 to $1.84 reaffirmed.
Board declared monthly dividends of $0.10167 per share for October, November and December 2025, totaling $0.305 for the fourth quarter.
Digital Realty reported third-quarter 2025 results on October 23, 2025, with revenue of $1.6 billion, up 10% from a year earlier, and Core FFO of $1.89 per diluted share, up from $1.67. The company raised its 2025 Core FFO per share outlook to $7.32-$7.38 from $7.15-$7.25, which signals higher expected cash earnings for shareholders this year.
Q3 2025 revenue of $1.6 billion, up 10% from the same quarter last year; net income available to common stockholders was $0.15 per diluted share, compared with $0.09 a year earlier.
Core FFO per diluted share of $1.89 versus $1.67 in Q3 2024; FFO per share of $1.65 versus $1.55.
2025 Core FFO per share outlook raised to $7.32-$7.38, up from $7.15-$7.25 in the July 24, 2025 outlook; total revenue outlook raised to $6.025-$6.075 billion.
Signed bookings expected to generate $201 million of annualized GAAP rental revenue at 100% share; backlog of signed-but-not-commenced leases was $852 million at quarter-end.
Harmony Biosciences said preliminary third-quarter 2025 net revenue for the WAKIX franchise was about $239 million, up 29% year over year, and raised its 2025 revenue guidance to $845 million-$865 million from $820 million-$860 million. The figures are preliminary and unaudited, and the company will report full third-quarter results on November 4, 2025.
WAKIX franchise net revenue of about $239 million in Q3 2025, up 29% year over year
Average patients reached 8,100 in Q3 2025, an increase of about 500 for the quarter
2025 revenue guidance raised to $845 million-$865 million from $820 million-$860 million
Results are preliminary and unaudited; full Q3 2025 results and conference call set for November 4, 2025
West Pharmaceutical Services reported third-quarter 2025 net sales of $804.6 million, up 7.7% from a year earlier, and diluted EPS of $1.92 versus $1.85. The company raised its full-year 2025 net sales guidance to $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to $7.06 to $7.11, and it introduced fourth-quarter guidance that is below the third-quarter level.
Q3 net sales $804.6 million (up 7.7%, organic up 5.0%); HVP Components rose 16.3% to $390.0 million
Q3 diluted EPS $1.92 vs. $1.85; adjusted-diluted EPS $1.96 vs. $1.85 a year earlier
Full-year 2025 adjusted-diluted EPS guidance raised to $7.06 to $7.11, from $6.65 to $6.85
Fourth-quarter 2025 net sales guidance of $790 million to $800 million and adjusted-diluted EPS guidance of $1.81 to $1.86
CBRE Group reported third-quarter 2025 results, with revenue up 14% to $10.3 billion and GAAP EPS up 66% to $1.21. The company raised its 2025 Core EPS outlook to $6.25 to $6.35 from $6.10 to $6.20, which points to higher expected profit for shareholders this year.
Q3 GAAP EPS $1.21 vs. $0.73 a year earlier; Core EPS $1.61, up 34%
Revenue $10.3 billion, up 14%; GAAP net income $363 million, up 61%
2025 Core EPS outlook raised to $6.25 to $6.35 from $6.10 to $6.20
Repurchased about 5.2 million shares for $663 million since year-end 2024; about $5.2 billion of authorization remained as of September 30, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.